Dr. Siobh?n N? Bhriain:

The Senator is absolutely right. It is always our aim to try to work with advocacy and patient groups in the HSE and in the development of our clinical programmes. That is a given. I have met with LCAI. We have a new clinical lead for infectious diseases who has met with LCAI. I was talking to my public health colleagues last night who are leading on the FADA study. They are very keen to ensure that LCAI stays engaged. When the time comes to review the model of care we will most certainly be engaging with patient and advocacy groups. That is very much a principle of how we work.